Cancer News |

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (09/26/2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab) to standard chemotherapy. ALL in children is a malignant disease, or cancer of the blood, characterized by the rapid uncontrolled growth of abnormal, … Continue reading "Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia"